Advertisement

Topics

Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate

2014-08-27 03:43:02 | BioPortfolio

Summary

End-stage renal disease (ESRD) is a state of increased arterial stiffness of extensive vessel calcifications, compared with the non-renal population. Both arterial stiffness and arterial calcifications are potent predictors of all-cause and cardiovascular mortality in ESRD patients. Several studies have documented the direct relationship between the extent and severity of arterial/coronary calcifications and outcome in dialysis patients. The relationship is strong no matter if arterial calcifications were quantified by electron-beam computed tomography or a radiological calcification score. Calcifications are early and progressive events in these patients. PWV is strongly related to the degree of sonographic determined arterial calcifications and EBCT-derived coronary artery calcium score in chronic kidney disease patients.

Calcium-based phosphate binders are associated with progressive coronary artery and aortic calcification, especially when mineral metabolism is not well controlled.

According to recent studies, sevelamer hydrochloride is a potent non-calcium-containing phosphate binder, well tolerated in ESRD. Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcemia, low levels of PTH, and progressive coronary and aortic calcification in hemodialysis patients. Moreover, sevelamer has a favorable effect on the lipid profile.

Less is known about the relationship between sevelamer treatment and progression of arterial stiffness. To date, there is one single study examining the influence of sevelamer (versus calcium carbonate) on the evolution of arterial stiffness in a very small number (N=15) of haemodialysis patients. These study used the same patients as historical controls, thus being methodologically rather weak. Moreover, the follow-up was quite short - 6 month.

The aim of the trial is to to quantify, in a randomized opened-labeled controlled trial the effect of sevelamer hydrochloride on the evolution of arterial stiffness parameters (pulse wave velocity and the augmentation index) in chronic haemodialysis patients and to correlate these parameters with arterial calcification assessed by a previous described radiological score of arterial calcification and echocardiographic parameters (left ventricular hypertrophy, LV dilatation, systolic and diastolic dysfunction).

Description

End-stage renal disease (ESRD) is a state of increased arterial stiffness of extensive vessel calcifications, compared with the non-renal population. Both arterial stiffness and arterial calcifications are potent predictors of all-cause and cardiovascular mortality in ESRD patients. Underlying mechanisms for increased stiffness in uremia are not well-defined, but may include: chronic fluid overload, arterial calcifications, microinflammation, increased sympathetic hyperactivity, activation of the renin-angiotensin system, increased lipid oxidation, and abnormalities of the nitric oxide system.

Several studies have documented the direct relationship between the extent and severity of arterial/coronary calcifications and outcome in dialysis patients. The relationship is strong no matter if arterial calcifications were quantified by electron-beam computed tomography or a radiological calcification score. Calcifications are early and progressive events in these patients. PWV is strongly related to the degree of sonographic determined arterial calcifications and EBCT-derived coronary artery calcium score in chronic kidney disease patients.

Calcium-based phosphate binders are associated with progressive coronary artery and aortic calcification, especially when mineral metabolism is not well controlled.

Sevelamer hydrochloride is a potent non-calcium-containing phosphate binder, well tolerated in ESRD. Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcemia, low levels of PTH, and progressive coronary and aortic calcification in hemodialysis patients. Moreover, sevelamer has a favorable effect on the lipid profile.

Less is known about the relationship between sevelamer treatment and progression of arterial stiffness. To date, there is one single study examining the influence of sevelamer (versus calcium carbonate) on the evolution of arterial stiffness in 15 HD patients. These study used the same patients as historical controls, thus being methodologically rather weak. Moreover, the follow-up was quite short - 6 month.

The aim of the study is to quantify, in a randomized opened-labeled controlled trial the effect of sevelamer hydrochloride on the evolution of arterial stiffness parameters (pulse wave velocity and the augmentation index) in chronic haemodialysis patients and to correlate these parameters with arterial calcification assessed by a previous described radiological score of arterial calcification and echocardiographic parameters (left ventricular hypertrophy, LV dilatation, systolic and diastolic dysfunction) 240 chronic clinical stable (young-to-medium-aged)haemodialysis patients will be included. Follow-up: 12 month After screening, the patients will enter a washout period for all currently used phosphate binders for 2 weeks. All patients with hyperphosphatemia (>1.8 mmol/l) during the wash-out period eligible for randomization into the treatment phase.

Stratification will consider the Framingham calcification score, age, gender, diabetes, HD vintage The patient will be randomized (computer-generated) in a 1:1 ratio to open label sevelamer (RenagelR) 800 mg tablets or calcium acetate 670 mg tablets. Because of the size, appearance and taste of the tablets, neither the subjects nor the investigators will be blinded.

Adherence to treatment will be assessed by regular bill count. The starting dose of sevelamer and calcium acetate determined by replacing the phosphate binder used by the patient prior to the washout period on a gram to gram basis. The dose of phosphate binder should be titrated to achieve a serum phosphorus level in the target range of 1-1.6 mmol/L and a serum calcium level <2.6 mmol/L. The maximum elemental calcium dose/day in the calcium acetate arm will not exceed 1.5 g.

Serum ionized calcium will be adjusted for the serum albumin concentration using the formula: adjusted Ca = total measured calcium +0.8 x (4.0-albumin g/dL). After 4 weeks, the dose of phosphate binder, vitamin D analogue and the dialysate calcium concentration can be titrated to reach the target range.

Study conduction will be conducted strictly in compliance with the Declaration of Helsinki and Committees on Human Research in the participating centers/Universities The K/DOQI targets for serum phosphate, serum-calcium and PTH are aimed during the study.

Data on intact parathormone, serum-calcium and phosphate, Ca-P product will be collected monthly in the first three month, every 3 month later on.

Vitamin D allowance only if during the study PTH raise > 500 pg/ml; vitamin D not at all if serum calcium >2.6 mmol/L

Analysis will include:

- correlation between PWV, AIx, calcification scores and Ca-P metabolism parameters, lipid parameters etc

- capability of reaching the N/KDOQI guidelines regarding control of secondary hyperparathyroidism - sevelamer hydrochloride versus calcium acetate

- stratification of PWV and AIx dynamics according to different categories The only published reference in the literature is by Takenaka et al (NDT 2005); they showed in a small study that after 6 months of sevelamer treatment PWV decreases from 14.56 m/s to 13.34 m/s i.e. a decrease of approximatively 9% from pre-Sevelamer values. If normalized to BP (PWV divided by corresponding BP level) than PWV/BP decreased from 10.2 m/s/mmHg to 9.3 m/s/mmHg - i.e. again a decrease of approximatively 9% from pre-Sevelamer values.

Of note, in the previous 6 months, while on CaCO3, PWV increased significantly by 30 to 40% from baseline study values (study of Takenaka has a cross-over design: 6-months on CaCO3 followed by 6-months on Sevelamer). Also there is no information provided on AIx. There is no information in the literature on the impact of Sevelamer on EID (GTN)- vascular function or on EDD (flow-dependent hyperemia or beta2 agonist stimulation)-vascular function.

In our experience, the mean PWV is 7.19+/-1.88 m/s, or if corrected for corresponding BP values: PWV/BP = 5.14 +/- 1.3 m/s/mmHg. AIx is typically 27.9±11.9% in HD patients.

If we assume that the Sevelamer group ("treatment group") will have the same 9% decrease in PWV at 6 months, from baseline, the Ca-binder group ("control group") will have no change (i.e. no increase in PWV - "conservative approach", but different from Takenaka's results where an increase in PWV was reported - see above), the standard deviation of the PWV is 1.88 m/s in our experience or 1.3 m/s/mmHg, the ratio of 1 between the control and thre treatment arms, than for a power of 80% and a confidence interval of 95% we need 108 patients in each arm (105 if PWV/BP is used), 216 total. This will also have sufficient power detect a decrease in AIx of only 4.6% or 16.5% from baseline in the treatment arm. This is usually less than that recorded after different acute interventions (GTN, salbutamol, dialysis session) or after transplantation in HD patients.

Compliance is good in our units and transplantation is rare. Therefore we expect only a dropout rate of 10%. Thus the final study population should be 240 patients. 120 patients should receive Sevelamer for 6 months.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Haemodialyzed Patients

Intervention

Calcium acetate, Sevelamer

Location

"Dr Carol Davila" Teaching Hospital of Nephrology
Bucharest
Romania
010731

Status

Not yet recruiting

Source

Romanian Society of Nephrology

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:43:02-0400

Clinical Trials [747 Associated Clinical Trials listed on BioPortfolio]

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique...

Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

The purpose of this study is to determine if Renagel® is more effective as a treatment for patients with peritoneal dialysis compared to calcium acetate.

Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calciu...

Different Effects of Non-calcium Phosphate Binders on Serum Calcium

Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium...

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In...

PubMed Articles [25791 Associated PubMed Articles listed on BioPortfolio]

Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.

Sucroferric oxyhydroxide (SFOH) is a non-calcium, iron-based phosphate binder that demonstrated sustained serum phosphorus (sP) control, good tolerability, and lower pill burden, vs. sevelamer carbona...

A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.

To evaluate the efficacy and safety of PA21 versus sevelamer in dialysis patients.

Comparison of hypoalbuminemia-corrected serum calcium using bcp albumin assay to ionized calcium and impact on prescribing in hemodialysis patients
.

Albumin-corrected calcium (cCa) is recommended over ionized calcium (iCa) in hemodialysis (HD) patients per the Kidney Disease: Improving Global Outcomes position statements due to cost and feasibilit...

Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma.

C-acetate uptake could be increased in physiologic or inflammatory conditions without evidence of cancer. We report a hepatocellular carcinoma patient with sorafenib-induced metabolic acidosis, who sh...

Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.

To determine the proportion and the characteristics of patients who did or did not respond after 3 months of ulipristal acetate (UPA) therapy.

Medical and Biotech [MESH] Definitions

A polymeric amine that binds phosphate and is used to treat HYPERPHOSPHATEMIA in patients with kidney disease.

Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.

An enzyme that catalyzes the conversion of acetate esters and water to alcohols and acetate. EC 3.1.1.6.

Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

A 6-methyl PROGESTERONE acetate with reported glucocorticoid activity and effect on ESTRUS.

More From BioPortfolio on "Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...


Searches Linking to this Trial